Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

748 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
Yoshida H, Kim YH, Sakamori Y, Nagai H, Ozasa H, Kaneda T, Yoshioka H, Nakagawa H, Tomii K, Okada A, Yoshimura K, Hirabayashi M, Hirai T. Yoshida H, et al. Among authors: kaneda t. Anticancer Res. 2020 May;40(5):2981-2987. doi: 10.21873/anticanres.14278. Anticancer Res. 2020. PMID: 32366452 Clinical Trial.
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M. Kim YH, et al. Among authors: kaneda t. Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30. Cancer Chemother Pharmacol. 2012. PMID: 22752216 Clinical Trial.
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, Hirai T. Ikeda S, et al. Among authors: kaneda t. Oncology. 2019;97(6):327-333. doi: 10.1159/000501967. Epub 2019 Aug 14. Oncology. 2019. PMID: 31412347 Clinical Trial.
Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
Hata A, Katakami N, Hattori Y, Tanaka K, Fujita S, Kotani Y, Nishimura T, Imamura F, Yokota S, Satouchi M, Monden K, Otsuka K, Nishiyama A, Tsubouchi K, Kaneda T, Yoshioka H, Morita S, Negoro S. Hata A, et al. Among authors: kaneda t. Cancer Chemother Pharmacol. 2017 Apr;79(4):689-695. doi: 10.1007/s00280-017-3259-z. Epub 2017 Mar 9. Cancer Chemother Pharmacol. 2017. PMID: 28280972 Clinical Trial.
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S. Otsuka T, et al. Among authors: kaneda t. Anticancer Res. 2015 Jul;35(7):3885-91. Anticancer Res. 2015. PMID: 26124334
748 results